Capital International Inc. CA Buys 22,054 Shares of The Cooper Companies, Inc. $COO

Capital International Inc. CA lifted its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 22.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 118,210 shares of the medical device company’s stock after acquiring an additional 22,054 shares during the quarter. Capital International Inc. CA’s holdings in Cooper Companies were worth $9,688,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in COO. JANA Partners Management LP bought a new stake in shares of Cooper Companies in the 3rd quarter valued at approximately $166,917,000. Alecta Tjanstepension Omsesidigt grew its stake in shares of Cooper Companies by 15.8% in the 3rd quarter. Alecta Tjanstepension Omsesidigt now owns 1,563,000 shares of the medical device company’s stock valued at $107,112,000 after purchasing an additional 213,500 shares during the period. DAVENPORT & Co LLC grew its stake in shares of Cooper Companies by 1,359.7% in the 4th quarter. DAVENPORT & Co LLC now owns 567,203 shares of the medical device company’s stock valued at $46,642,000 after purchasing an additional 528,346 shares during the period. Swiss Life Asset Management Ltd grew its stake in shares of Cooper Companies by 63.9% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 49,409 shares of the medical device company’s stock valued at $3,387,000 after purchasing an additional 19,264 shares during the period. Finally, Fluent Financial LLC bought a new stake in shares of Cooper Companies in the 4th quarter valued at approximately $3,517,000. Institutional investors own 24.39% of the company’s stock.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Cooper Companies Price Performance

NASDAQ:COO opened at $67.34 on Monday. The stock’s fifty day moving average price is $65.09 and its two-hundred day moving average price is $74.54. The Cooper Companies, Inc. has a 52-week low of $58.89 and a 52-week high of $89.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. The company has a market cap of $13.14 billion, a price-to-earnings ratio of 57.07, a P/E/G ratio of 1.73 and a beta of 0.88.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.11. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the business earned $0.96 EPS. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. On average, analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Citigroup reiterated a “neutral” rating and issued a $69.00 price objective (down from $80.00) on shares of Cooper Companies in a research note on Thursday, May 28th. JPMorgan Chase & Co. decreased their price target on Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a research report on Friday. Wall Street Zen upgraded Cooper Companies from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Stifel Nicolaus decreased their price target on Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Wells Fargo & Company restated a “sell” rating and set a $66.00 price target (down from $82.00) on shares of Cooper Companies in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $82.64.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.